The role of endothelial-to-mesenchymal transition in cancer progression.
Recent evidence has demonstrated that endothelial-to-mesenchymal transition (EndMT) may have a significant role in a number of diseases. Although EndMT has been previously studied as a critical process in heart development, it is now clear that EndMT can also occur postnatally in various pathologic settings, including cancer and cardiac fibrosis. During EndMT, resident endothelial cells delaminate from an organised cell layer and acquire a mesenchymal phenotype characterised by loss of cell-cell junctions, loss of endothelial markers, gain of mesenchymal markers, and acquisition of invasive and migratory properties. Endothelial-to-mesenchymal transition -derived cells are believed to function as fibroblasts in damaged tissue, and may therefore have an important role in tissue remodelling and fibrosis. In tumours, EndMT is an important source of cancer-associated fibroblasts (CAFs), which are known to facilitate tumour progression in several ways. These new findings suggest that targeting EndMT may be a novel therapeutic strategy, which is broadly applicable not only to cancer but also to various other disease states.
Potenta
S
S
Division of Matrix Biology, Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA.
Zeisberg
E
E
Kalluri
R
R
D000818:Animals; D002454:Cell Differentiation; D018450:Disease Progression; D042783:Endothelial Cells / Q000166:cytology / Q000473:pathology*; D005347:Fibroblasts / Q000473:pathology; D005355:Fibrosis; D006321:Heart / Q000196:embryology; D006801:Humans; D008648:Mesoderm / Q000166:cytology / Q000473:pathology*; D009206:Myocardium / Q000473:pathology; D009369:Neoplasms / Q000473:pathology*; D018919:Neovascularization, Physiologic; D015398:Signal Transduction
Cancer Res. 2007 Nov 1;67(21):10123-8
17974953
Nat Cell Biol. 2000 Feb;2(2):84-9
10655587
Am J Anat. 1977 Jan;148(1):85-119
842477
Am J Physiol Lung Cell Mol Physiol. 2007 Jul;293(1):L1-8
17384082
Nat Rev Mol Cell Biol. 2006 Feb;7(2):131-42
16493418
J Clin Invest. 2007 Feb;117(2):482-91
17273560
Dev Biol. 1975 Jan;42(1):160-80
1112439
Proc Natl Acad Sci U S A. 2003 Sep 16;100(19):10623-8
12963823
Dev Biol. 1989 Aug;134(2):392-401
2744239
Nat Cell Biol. 2000 Feb;2(2):76-83
10655586
Development. 1997 Jul;124(13):2659-70
9217007
Nat Med. 2007 Aug;13(8):952-61
17660828
Circ Res. 2005 Sep 16;97(6):512-23
16166562
Nature. 2001 Nov 1;414(6859):105-11
11689955
Circ Res. 2002 Jun 14;90(11):1189-96
12065322
Circ Res. 2004 Apr 16;94(7):910-7
14988227
J Cell Biol. 2003 Jun 23;161(6):1163-77
12810700
J Am Soc Nephrol. 2008 Dec;19(12):2282-7
18987304
J Biol Chem. 2003 Jan 10;278(2):1303-9
12417591
Genes Dev. 2004 Jan 1;18(1):99-115
14701881
J Cell Biochem. 2007 Jul 1;101(4):816-29
17243120
Nat Rev Mol Cell Biol. 2002 Mar;3(3):155-66
11994736
Nat Rev Cancer. 2006 May;6(5):392-401
16572188
Anat Rec. 2000 Feb 1;258(2):119-27
10645959
Dev Biol. 2000 Jul 1;223(1):91-102
10864463
Circ Res. 2004 Sep 3;95(5):459-70
15345668
Circ Res. 2005 Nov 25;97(11):1093-107
16306453
Int J Exp Pathol. 2006 Dec;87(6):463-74
17222214
Exp Eye Res. 2006 Dec;83(6):1309-16
16769055
Nat Rev Mol Cell Biol. 2002 May;3(5):349-63
11988769
J Clin Invest. 2002 Aug;110(3):341-50
12163453
Biull Eksp Biol Med. 1988 Apr;105(4):501-3
3359040
Oncogene. 2005 Aug 29;24(37):5764-74
16123809
Anat Embryol (Berl). 2000 Feb;201(2):103-9
10672362